Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals’ (RCE) phase I/II trial partner has wrapped up the second-stage dosages of its ongoing trial
- A third cohort of patients is now being recruited ahead of schedule
- The company’s flagship anti-infective UTI product remains well tolerated by patients at higher dosages
- An independent committee will now review the safety data following good safety outcomes in phase one
- Recce shares are up 5.19 per cent, trading at 71 cents at 11:17 am AEST
Recce Pharmaceuticals (RCE) has completed the dosing schedule in its ongoing phase I/II trial for UTI anti-infective and flagship product Recce 327 (R327).
The company’s project partner in NSW, Scientia, has wrapped up the increased 2500mg IV dosage schedule following promising safety data from phase one of the trial that revealed no safety concerns.
Dosages were increased to 2500mg and IV transfusion rates were shortened as the company works to make R327 the most seamless treatment possible.
So far, patients have tolerated that dosage well.
Not only that, but the drug is proving superior compared to competitors at what it’s designed to do – eliminate bacteria in urine.
The move reflects a company ticking every box, given that the phase I/II trial is already ahead of schedule.
An independent safety committee is to review the data once phase I/II is finalised and remains present as the trial carries on. Recruitment for the next cohort of the trial is already underway with male and female patients both present.
“R327 via two faster infusion rates of 2500mg across male and female subjects continues to be shown as safe and well tolerated,” Recce CEO James Graham said.
“Completing dosing well ahead of schedule is a welcomed confirmation that we are on track in achieving study objectives.”
Recce shares were up 5.19 per cent, trading at 71 cents at 11:17 am AEST.
